#compasspathways

  1. Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More

    By Lara Goldstein John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary halt on December 8, 1980 , when news that John Lennon was shot and killed as he approached his apartment building in New Y
  2. Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds

    By Lara Goldstein A COMPASS Pathways (NASDAQ: CMPS )-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin. Published by the Journal of the
  3. Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More

    By Lara Goldstein Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by bi
  4. UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

    By Lara Goldstein The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS ) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD
  5. The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

    By Faith Ashmore Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant depression (TRD),
  6. Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More

    By Lara Goldstein Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive
  7. How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

    By Faith Ashmore Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient c
  8. One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

    By Faith Ashmore Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to
  9. What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field

    By Rachael Green In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS ), consisting of an initial investment of $125 million and the potential for an additional investment of
  10. Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures

    By Lara Goldstein The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by its forwarders the MAPS Public Benefit Corporation and COMPASS Pa